Brainstorm Cell Therapeutics (GHD) Stock Statistics & Valuation Metrics
Total Valuation
Brainstorm Cell Therapeutics has a market cap or net worth of EUR 8.85M. The enterprise value is EUR 12.39M.
- Market Cap
- EUR 8.85M
- Enterprise Value
- EUR 12.39M
Share Statistics
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 11,034,775
- Owned by Insiders
- 28.36%
- Owned by Institutions
- 1.35%
Financial Efficiency
Brainstorm Cell Therapeutics’s return on equity (ROE) is 1.00 and return on invested capital (ROIC) is 98.70%.
- Return on Equity (ROE)
- 1.00
- Return on Assets (ROA)
- -14.42
- Return on Invested Capital (ROIC)
- 98.70%
- Return on Capital Employed (ROCE)
- 0.97
- Revenue Per Employee
- 0
- Profits Per Employee
- -542.47K
- Employee Count
- 19
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Brainstorm Cell Therapeutics is -1.00. Brainstorm Cell Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.00
- PS Ratio
- 0.00
- PB Ratio
- -0.90
- Price to FCF
- -2.58
- Price to Operating Cash Flow
- -2.58
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 0 and earned -10.31M in profits. Earnings per share was -1.11.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -9.95M
- Pretax Income
- -10.31M
- Net Income
- -10.31M
- EBITDA
- -9.75M
- Earnings Per Share (EPS)
- -1.11
Cash Flow
In the last 12 months, operating cash flow was -4.06M and capital expenditures 0, giving a free cash flow of -4.06M billion.
- Operating Cash Flow
- -4.06M
- Free Cash Flow
- -4.06M
- Free Cash Flow per Share
- -0.37
Dividends & Yields
Brainstorm Cell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -39.96%
- Earnings Yield
- -103.64%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 2.69
- 200-Day Moving Average
- 2.69
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Brainstorm Cell Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Brainstorm Cell Therapeutics as a current ratio of 0.03, with Debt / Equity ratio of -2.02%
- Current Ratio
- 0.03
- Quick Ratio
- 0.03
- Debt to Market Cap
- 0.04
- Net Debt to EBITDA
- -0.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Brainstorm Cell Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Brainstorm Cell Therapeutics EV to EBITDA ratio is -1.18, with an EV/FCF ratio of -2.84.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.18
- EV to Free Cash Flow
- -2.84
- EV to Operating Cash Flow
- -2.84
Balance Sheet
Brainstorm Cell Therapeutics has EUR 22.00K in cash and marketable securities with EUR 1.37M in debt, giving a net cash position of -EUR 1.35M billion.
- Cash & Marketable Securities
- EUR 22.00K
- Total Debt
- EUR 1.37M
- Net Cash
- -EUR 1.35M
- Net Cash Per Share
- -EUR 0.12
- Tangible Book Value Per Share
- -EUR 1.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Brainstorm Cell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
